Key result
Pegylated liposomal doxorubicin and paclitaxel yield ~48% response rate without cardiac toxicity in breast cancer.
Why the study?
The combination of paclitaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer but may cause congestive heart failure, and liposome-encapsulated doxorubicin offers a formulation with no dose-limiting cardiac toxicity.
Does the combination of pegylated liposomal doxorubicin and paclitaxel improve response rates without causing cardiac toxicity in patients with previously treated metastatic breast cancer?
Comparison
Pegylated liposomal doxorubicin plus paclitaxel treatment
Design
Case series
Authors
Loading...
Supports further investigation in pretreated metastatic breast cancer; leaves open comparative efficacy and durability in randomized trials.
Does the combination of pegylated liposomal doxorubicin and paclitaxel improve response rates without causing cardiac toxicity in patients with previously treated metastatic breast cancer?
The combination of pegylated liposomal doxorubicin and weekly paclitaxel is highly effective for previously treated metastatic breast cancer and avoids the dose-limiting cardiac toxicity typically associated with conventional doxorubicin.
Schwonzen et al. (2000) studied metastatic breast cancer (n=21). Pegylated liposomal doxorubicin and paclitaxel was evaluated on Response rate (complete and partial remissions). Pegylated liposomal doxorubicin combined with weekly paclitaxel achieved a 48% response rate in previously treated metastatic breast cancer patients, with no cardiac toxicity observed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: